The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS)

2018 ◽  
Vol 34 (3) ◽  
pp. e2974 ◽  
Author(s):  
Tae Nyun Kim ◽  
Man Sik Park ◽  
Eun Joo Lee ◽  
Hye Soo Chung ◽  
Hye Jin Yoo ◽  
...  
Keyword(s):  
Muscle Mass ◽  
Advanced Glycation End Products ◽  
Sarcopenic Obesity ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shou-En Wu ◽  
Yi-Lin Chiu ◽  
Tung-Wei Kao ◽  
Wei-Liang Chen
Keyword(s):  
Muscle Mass ◽  
Advanced Glycation End Products ◽  
Community Dwelling ◽  
Enzyme Linked Immunosorbent Assay ◽  
Health Examination ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Srage Level ◽  
Glycation End Products ◽  
End Products

Abstract Background The soluble receptor for advanced glycation end products (sRAGE) has been proposed to serve as a marker for disease severity, but its role in sarcopenia, an age-related progressive loss of muscle mass and function, remains elusive. This study examines the association between sRAGE and sarcopenia. Methods A total of 314 community-dwelling elderly adults who had their health examination at Tri-Service General Hospital from 2017 to 2019 underwent protein analysis with enzyme-linked immunosorbent assay. The relationship with sarcopenia and its detailed information, including components and diagnosis status, were examined using linear and logistic regressions. Results As for sarcopenia components, low muscle mass (β = 162.8, p = 0.012) and strength (β = 181.31, p = 0.011) were significantly correlated with sRAGE, but not low gait speed (p = 0.066). With regard to disease status, confirmed sarcopenia (β = 436.93, p < 0.001), but not probable (p = 0.448) or severe sarcopenia (p = 0.488), was significantly correlated with sRAGE. In addition, females revealed a stronger association with sRAGE level by showing significant correlations with low muscle mass (β = 221.72, p = 0.014) and low muscle strength (β = 208.68, p = 0.043). Conclusions sRAGE level showed a positive association with sarcopenia, illustrating its involvement in the evolution of sarcopenia. This association is more evident in female groups, which may be attributed to the loss of protection from estrogen in postmenopausal women. Utilizing sRAGE level as a prospective marker for sarcopenia deserves further investigation in future studies.

Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria

2015 ◽  
Vol 13 (2) ◽  
pp. 259-264
Author(s):  
Huan Zheng ◽  
Lingyan Yuan ◽  
Nanzi Xie ◽  
Huifeng Xu ◽  
Xiaoyun Xie ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score

2011 ◽  
Vol 107 (6) ◽  
pp. 938-944 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Bruno K. Rodiño-Janeiro ◽  
Lilian Grigorian-Shamagian ◽  
María Moure-González ◽  
Ana Seoane-Blanco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Louise J. N. Jensen ◽  
Allan Flyvbjerg ◽  
Mette Bjerre
Keyword(s):  
Acute Coronary Syndrome ◽  
Advanced Glycation End Products ◽  
Acute Ischemia ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Coronary Syndrome ◽  
Potential Biomarker ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease

The receptor of advanced glycation end products (RAGE) and its ligands are linked to the pathogenesis of coronary artery disease (CAD), and circulating soluble receptor of advanced glycation end products (sRAGE), reflecting the RAGE activity, is suggested as a potential biomarker. Elevated sRAGE levels are reported in relation to acute ischemia and this review focuses on the role of sRAGE as a biomarker for the acute coronary syndrome (ACS). The current studies demonstrated that sRAGE levels are elevated in relation to ACS, however during a very narrow time period, indicating that the time of sampling needs attention. Interestingly, activation of RAGE may influence the pathogenesis and reflection in sRAGE levels in acute and stable CAD differently.

Sign in / Sign up

Export Citation Format

Share Document